Introduction
Activated B cell (ABC), a subset of diffuse large B cell lymphoma (DLBCL), is characterized by an aberrant activation of the NF-κB signaling pathway, conferring poor prognosis when treated with standard chemotherapy regimens (1) (2) (3) (4) . In ABC DLBCL, a variety of genetic alterations that aberrantly activate the B cell receptor (BCR) and TLR signaling pathways have been linked to the constitutive activation of NF-κB (5) . In the BCR pathway, mutations in CD79 and CARD11 are the most frequently observed genetic alterations, whereas L265P mutation of the signaling adaptor MyD88 is the most frequent one that constitutively activates the TLR pathway (6) . Knockdown of either CD79 or MyD88 has been shown to inhibit proliferation of ABC DLBCL cells, suggesting that pharmacologic targeting of these 2 pathways may have a therapeutic value for the treatment of ABC DLBCL (5, 6) .
In the BCR pathway, selective targeting of the bruton tyrosine kinase (BTK) has been shown to inhibit NF-κB activation and to induce cell death of ABC DLBCL (5, 7) . At the present time, there is no drug available that can directly inhibit MyD88. However, because IL-1 receptor-associated kinase 4 (IRAK4) mediates most of the biological functions of MyD88, recent investigation has focused on selective targeting of IRAK4 in diseases driven by aberrant MyD88 signaling (8) . While the BCR and TLR pathways converge distally to activate NF-κB, they may also crosstalk proximally in certain lymphoma subtypes. This complex interaction resulted in conflicting reports on the role of MyD88 mutations in mediating resistance to BCR pathway-targeted agents, such as ibrutinib. In ABC DLBCL, isolated MyD88 mutations were associated with resistance to ibrutinib, whereas lymphomas with concurrent MyD88 and CD79 mutations remained sensitive to ibrutinib (9) . Nevertheless, these responses where mainly partial and of a short duration, raising the question of whether a combined inhibition of MyD88 and ibrutinib would have resulted in a better treatment outcome.
Diffuse large B cell lymphoma (DLBCL) frequently harbors genetic alterations that activate the B cell receptor (BCR) and TLR pathways, which converge to activate NF-κB. While selective inhibition of BTK with ibrutinib causes clinical responses in relapsed DLBCL patients, most responses are partial and of a short duration. Here, we demonstrated that MyD88 silencing enhanced ibrutinib efficacy in DLBCL cells harboring MyD88 L265P mutations. Chemical downregulation of MyD88 expression with HDAC inhibitors also synergized with ibrutinib. We demonstrate that HDAC inhibitor regulation of MyD88 expression is mediated by STAT3. In turn, STAT3 silencing caused a decrease in MyD88 mRNA and protein levels, and enhanced the ibrutinib antilymphoma effect in MyD88 mutant DLBCL cells. Induced mutations in the STAT3 binding site in the MyD88 promotor region was associated with a decrease in MyD88 transcriptional activity. We also demonstrate that treatment with the HDAC inhibitor panobinostat decreased phosphorylated STAT3 binding to the MyD88 promotor. Accordingly, combined treatment with panobinostat and ibrutinib resulted in enhanced inhibition of NF-κB activity and caused regression of DLBCL xenografts. Our data provide a mechanistic rationale for combining HDAC inhibitors and ibrutinib for the treatment of DLBCL.
In the present study, we examined the potential therapeutic value of dual inhibition of the BCR and TLR pathways in DLBC. We found that genetic silencing of MyD88 enhanced the efficacy of ibrutinib in ABC DLBCL carrying MyD88 mutations. We also report that histone deacetylase inhibitors (HDACi) transcriptionally downregulated MyD88, inhibited MyD88-driven NF-κB activation, and enhanced ibrutinib efficacy in MyD88 mutant ABC DLBCL. Furthermore, we describe a central role of STAT3 in mediating HDACi regulation of MyD88 transcription. Our data provide a mechanistic rationale for combining HDACi with ibrutinib in ABC DLBCL.
Results
MyD88 mutation sustains ABC DLBCL survival and attenuates the antiproliferative activity of ibrutinib. To evaluate the sensitivity of DLBCL cells to ibrutinib treatment, we treated a panel of 9 human lymphoma cell lines (6 ABC and 3 germinal center B cell-like [GCB]) with increasing drug concentrations (0.01-0.075 μM) for 24 hours. Ibrutinib showed lower efficacy in the ABC lymphoma cell lines with MyD88 L265P mutation compared with those with WT MyD88 and was not effective in the GCB cells (Supplemental Figure 1A ; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.90196DS1). Knockdown of MyD88 using a small interfering RNA (siRNA) (Supplemental Figure 1B) enhanced ibrutinib efficacy in ABC cells bearing MyD88 L265P mutation, but did not enhance those with MyD88 WT or in the GCB subtype ( Figure 1A ). To further investigate the contribution of mutant MyD88 to ibrutinib resistance, we used tetracycline-inducible shRNA to knock down MyD88 in 2 ABC cell lines (HBL-1 and Ri-1, MyD88 mutant and WT, respectively) and 1 GCB (SUDHL-4) cell line (Supplemental Figure 1C) . MyD88 knockdown enhanced ibrutinib efficacy in HBL-1 but not in Ri-1 or SUDHL-4. Notably, after the doxycyxline washout from the culture media, MyD88 expression rebounded and HBL-1 became less sensitive to ibrutinib ( Figure 1B) . Overexpression of the constitutively activated MyD88 mutant L265P in Ri-1 cells ( Figure 1C and Supplemental Figure 2A ) resulted in activation of the NF-κB pathway (Supplemental Figure 2B ), enhanced proliferation and survival (Supplemental Figure 2 , C and D), and decreased ibrutinib efficacy ( Figure 1D ). Ibrutinib treatment of the Ri-1 parent cell line was associated with profound inhibition of the NF-κB pathway, which was not observed in the Ri-1 cells that stably expressed MyD88 mutation ( Figure 1E ). Collectively, these data demonstrate that MyD88 L265P mutation enhances ABC DLBCL survival and may attenuate the antiproliferative activity of ibrutinib in DLBCL. Our data suggest that dual inhibition of BTK and MyD88 may provide more potent antitumor activity in ABC DLBCL harboring MyD88 mutation.
HDACis transcriptionally regulate MyD88 expression. Previous studies demonstrated that bromodomain and extraterminal domain protein inhibitors (BETis) inhibited oncogenic NF-κB activity in ABC DLBCL by reducing IκB kinase (IKK) activity (10) . We investigated whether BETi-induced inhibition of NF-κB activity is mediated by regulating MyD88 expression and whether other epigenetic modifying agents, such as HDACis, have a similar effect. HDACis and BETis reduced MyD88 protein abundance in the HBL1 cells irrespective of poly (ADP-ribose) polymerase (PARP) cleavage (Figure 2A ). The decrease in MyD88 protein level was due to inhibition of MyD88 transcription, which was evident as early as at 3 hours of incubation ( Figure 2B ). Treatment with HDACis inhibited MyD88 transcription independent of the cell of origin or MyD88 mutation status ( Figure 2C ). This was also observed at the protein level, as determined by an ELISA assay ( Figure 2D ) or Western blotting ( Figure 2E ). To identify which HDAC isoform is responsible for downregulating MyD88, we knocked down each individual HDAC using 4 hairpins per gene. Multiple HDACs were found to be involved in regulating MyD88 expression, with the strongest MyD88 inhibition observed with HDAC1 and HDAC7 silencing (Supplemental Figure 3) .
HDACi transcriptionally regulates MyD88 expression by a STAT3-dependent mechanism. Using a luciferase-based promoter assay with the MyD88 promoter, we observed decreased luciferase activity in a time-dependent manner when ABC cell lines (HBL-1 and OCI-LY-10) and GCB (SUDHL-4) cell line were treated with HDACi ( Figure 2F ). MyD88 gene expression is regulated by multiple regulatory domains in the promoter region (11, 12) . Accordingly, we examined the effect of HDACi on the expression of transcription factors that are known to interact with MyD88 promotor. HDACi-induced downregulation of MyD88 was associated with a significant decrease in STAT3 phosphorylation (tyrosine 705 [T705]) (Supplemental Figure 4A ). ABC cell lines had a higher level of phosphorylated STAT3 at base line compared with GCB cell lines and were more prone to HDACi-induced STAT3 dephosphorylation ( Figure 3A) . In contrast, HDACi treatment had no effect on pSTAT1 (T701) (Supplemental Figure 4B) . A concomitant decrease in pSTAT3 (T705) and MyD88 Figure 4C ). Because the acetylated Lys 685 is situated on the same SH2 domain where tyrosine residue 705 is located (13) , our data indicate that HDACi-induced STAT3 lysine acetylation may interfere with T705 phosphorylation and consequently inhibit STAT3 activation (14) .
To confirm the role of STAT3 in regulating MyD88 expression, we silenced STAT3 gene expression using siRNA. STAT3 silencing was associated with a decrease in MyD88 protein levels ( Figure 3C and Supplemental Figure 4 , D and E) and mRNA levels (Supplemental Figure 4F ). These changes were associated with an enhanced sensitivity of MyD88 mutant ABC cells to ibrutinib ( Figure 3D and Supplemental Figure 4G ). This effect was specific for MyD88 mutant cells, as knockdown of STAT3 did not increase the efficacy of ibrutinib in MyD88 WT ABC cells ( Figure 3D ) or in GCB cell lines (Supplemental Figure 3G) . A second siRNA targeting construct for STAT3 was used in order to exclude a potential off-target effect and confirmed our data (Supplemental Figure 4 , H and I). To further demonstrate the role of STAT3 in mediating an HDACi regulatory effect on MyD88 expression, we mutated the STAT3 binding site in the MyD88 promotor region (15) ( Figure 3E ). Cells with a STAT3 mutant binding site had a decrease in MyD88 luciferase activity compared with cells with a WT MyD88 promoter. No further decrease of luminescence was observed in the mutant cells treated with either panobinostat or romidepsin to the mutant cells ( Figure 3F ).
Using a ChIP qPCR assay, panobinostat treatment decreased pSTAT3 (T705) binding to the MyD88 promoter in a time-dependent manner ( Figure 3G ). In accordance to this, we also observed a marked reduction of the H3K4me3 binding that marks active transcriptional promoters at MyD88 promoter in response to panobinostat (Supplemental Figure 4F) . Collectively, these data demonstrate a critical role for STAT3 in mediating HDACi regulation of MyD88 expression.
Panobinostat enhances ibrutinib activity in MyD88 mutant ABC DLBCL lines. Next, we determined whether HDACi-mediated downregulation of MyD88 enhanced ibrutinib antilymphoma activity. We found that the combination of panobinostat and ibrutinib is synergistic in ABC DLBCL cell lines carrying MyD88 mutations but not in GCB cells or ABC DLBCL with MyD88 WT (Figure 4 , A and B, and Supplemental Figure 5A ). Moreover, this combination also demonstrated a synergistic antitumor effect in Ri-1 cells that were induced to stably express the MyD88 mutant L265P but did not demonstrate it in the WT ( Figure  4C ). Taken together, these data confirm the relevance of the MyD88 mutation status in predicting an attenuated response to ibrutinib therapy and support a combination strategy with HDACis.
Given the convergence of BTK and MyD88 on NF-κB pathway, we investigated whether the combination of HDACis and ibrutinib is associated with an enhanced inhibition of NF-κB. As shown in Figure  4D , the combination of panobinostat and ibrutinib was more effective than either drug alone in decreasing NF-κB-luciferase activity. Similarly, the combination of panobinostat and ibrutinib was more effective than either drug alone in decreasing IKK-β and IRF4 levels in MyD88 mutant cells (Supplemental Figure 5B) , which are associated with a stronger NF-κB and STAT3 activation status (Supplemental Figure 5 , C and D). Because autocrine IL-6 and IL-10 production has been demonstrated to be regulated by JAK-STAT3 and MyD88 signaling in ABC DLBCL (6, 8, 16) , we investigated the effect of panobinostat and ibrutinib on the level of these cytokines. The combination of the 2 drugs was more potent than either drug alone in decreasing IL-6 and IL-10 levels in the supernatants of 3 ABC DLBCL cell lines, which is consistent with an enhanced inhibitory effect on NF-κB signaling pathway ( Figure 4E and Supplemental Figure 5E ). Since IL-6 and IL-10 have been demonstrated to increase STAT3 phosphorylation (17), we evaluated the effect of these 2 cytokines on MyD88 transcription. HBL-1 cells were induced with 100 ng/ml of rIL-6 and rIL-10 for 30 minutes, 3 hours, and 6 hours. MyD88 mRNA expression increased in a time-dependent manner, with the maximal increase observed at 6 hours (Supplemental Figure 5F ). Using a luciferase-based promoter assay with the MyD88 promoter, we confirmed the stimulatory effect of IL-6 and IL-10 on MyD88 in 2 representative ABC (HBL-1 and OCI-LY-10) cell lines and 1 GCB (SUDHL-4) cell line (Supplemental Figure 5G) . Taken together, these data suggest the existence of an amplification loop that links MyD88 and JAK-STAT signaling through IL-6 and IL-10 ( Figure 5 ). mutant + ibrutinib viability data were normalized to the effect of MyD88 mutant alone. Error bars represent SEM of triplicate experiments. Differences between groups were calculated with the Student t test. ****P < 0.0001. (E) Representative Western blot demonstrating inhibition of NF-κB pathway (pNF-κB p65, IRF4, pSTAT3 (T705]) after treatment with increasing concentrations of ibrutinib (0.1, 0.25, 0.5, 0.75 μM) for 24 hours in Ri-1 MyD88 WT but not in the Ri-1 stably expressing MyD88 mutation. Figure 6A ). Both panobinostat and the combination of panobinostat and ibrutinib demonstrated antitumor efficacy. However, when the animals were observed after 3 weeks of therapy, mice with MyD88 mutant tumor that were treated with single agent panobinostat demonstrated rapid regrowth of their tumors, whereas no tumor relapse was observed in animals that were treated with the combination of panobinostat with ibrutinib ( Figure 6B ). Mice with WT MyD88 had a similar pattern of disease progression among different treatment groups ( Figure 6B) . Futhermore, the combination therapy improved survival of mice with MyD88 mutant lymphoma compared with mice with WT lymphoma ( Figure 6C ). Overall, panobinostat and ibrutinib were well tolerated, as therapy did not induce a significant weight loss compared with mice treated with each drug alone or vehicle (Supplemental Figure 6) .
We further confirmed these results using Ri-1 cells that were induced to stably express the MyD88 mutant L265P in a xenograft model. The combination of panobinostat and ibrutinib was more effective than either drug alone in the mutant but not in the WT tumor model (Supplemental Figure 7A) . Furthermore, when treatment was stopped after 3 weeks, a sustained antitumor effect was observed in the mutant but not in the WT tumor model (Supplemental Figure 7B) . Finally, the 2-drug combination also improved survival in the mutant but not in the WT tumor model (Supplemental Figure 7C ).
Discussion
ABC DLBCL is a molecularly defined subgroup of DLBCL with a poor prognosis when treated with standard chemotherapy regimens (1-4) . The recent discovery of recurrent genetic alterations in the BCR and TLR signaling pathways identified potential vulnerable mechanisms that can be explored therapeutically (5, 6). One such example is the use of ibrutinib, a selective BTK inhibitor, which showed promising clinical activity in patients with relapsed ABC DLBCL (9) . In a trial that involved 80 patients with relapsed or refractory DLBCL, ibrutinib produced a 37% response rate of those with ABC DLBCL. However, most responses were partial and of a short duration (9) . This prompted us to search for other vulnerable mechanisms that can be therapeutically explored in combination with ibrutinib. In this study, we focused our attention on the interaction between the BCR pathway and TLR pathway by exploring the potential role of targeting MyD88.
We demonstrated that genetic silencing of mutant MyD88 enhanced ibrutinib efficacy in ABC DLB-CL. Conversely, ectopic expression of mutant L265P MyD88 gene resulted in ibrutinib resistance. Our data indicated that dual inhibition of BTK and MyD88 is more effective as an antiproliferative strategy against ABC DLBCL and should be explored therapeutically. Interestingly, ibrutinib as a single agent demonstrated a high efficacy in Waldenström's Macroglobulinemia (WM), in which MyD88 mutation is highly prevalent (18) (19) (20) . However, most responses were partial, raising the possibility that downregulation of MyD88 may have improved the quality of responses and treatment outcome of ibrutinib in this disease.
Our data demonstrated that HDACi can inhibit MyD88 transcription via a STAT3-dependent mechanism. This observation provided an opportunity to explore the efficacy of the combination of HDACi and 05 μM) or DMSO, and ChIP was performed with pSTAT3 (T705) antibody or control IgG. Primers to amplify the STAT3-binding regions of the MyD88 promoter were used in qPCR to determine fold enrichment relative to a noncoding region. Error bars represent SEM of 3 independent experiments. ANOVA with Dunnett's test was performed to compare STAT3 WT binding site versus the other conditions. *P < 0.05; **P < 0.005; ***P < 0.0005. (21-24) . The availability of clinical data from each drug alone will facilitate the design and interpretation of clinical trials using the 2-drug combination. Alternatively, one can explore combining ibrutinib with other investigational agents targeting downstream kinases of MyD88, such as IRAK4.
Given the fact that HDACi have broad biologic activities, we attempted to identify which HDAC isoform is responsible for downregulating MyD88. Our goal was to design a combination regimen that is mechanistically more selective and, therefore, potentially less toxic. Using a loss-of-function shRNA library screening, we found several HDACs to moderately downregulate MyD88, but only HDAC1 and HDAC7 robustly downregulated MyD88 in the 2 cell lines that were examined. However, within the confinement of our study, it seems that more than one HDAC is involved in regulating MyD88. As we showed in the in vivo animal studies, we are reassured that the combination of a pan-HDACi, such as panobinostat, with ibrutinib seems to be well tolerated. Whether more chronic administration of this combination is also tolerable will need to be determined in the context of a phase-I clinical trial.
In this study, we identified STAT3 as a transcription factor involved in regulating MyD88 expression upon HDACi treatment. Nevertheless, the mechanism underlying the HDAC-mediated regulation of STAT3 remains unclear. Previous studies suggested that HDACi treatment may increase STAT3 acetylation at Lys 685 while decreasing STAT3 phosphorylation at T705. These 2 posttranslational modifications may be mutually exclusive because both are located on the same SH2 domain; therefore, STAT3 lysine acetylation might prevent its tyrosine phosphorylation (13, 14) . Our data also suggest that the decrease in STAT3 phosphorylation might also be secondary to the decrease in cytokine production, such as IL-6 and IL-10 (16, 17) . Treatment with IL-6 or IL-10 increased STAT3 phosphorylation (17) and MyD88 transcriptional activity, supporting the presence of an amplification loop, which links MyD88 and JAK-STAT signaling through IL-6 and IL-10. Collectively, our study provides preclinical rationale for evaluating the combination of HDACis, such as panobinostat, with ibrutinib in ABC DLBCL.
Methods
Cell lines and reagents. The human DLBCL-derived cell lines SUDHL-4, SUDHL-6, U-2932, and Ri-1 were obtained from the German Collection of Microorganisms and Cell Cultures, Department of Human and Animal Cell Cultures (Braunschweig, Germany); SUDHL-8 was obtained from ATCC. The DLBCL-derived cell lines (HBL-1, TMD-8) were provided by Richard E. Davis (Houston, Texas, USA). The cell lines OCI-LY-10 was provided by Ethel Cesarman (New York, New York, USA). All cell lines were grown to log phase at 37 °C, in the presence of 5% CO 2 and cultured in RPMI 1640 medium supplemented with 10%-20% heatinactivated FBS (Hyclone, GE Healthcare Life Sciences), 1% L-glutamine, and penicillin-streptomycin in a humid environment of 5% CO 2 at 37°C. OCI-LY-10 was cultured in Hyclone Iscove's Modified Dulbecco's Medium (GE Healthcare Life Sciences) with 20% heat-inactivated FBS (Hyclone, GE Healthcare Life Sciences), 1% penicillin-streptomycin, 0.1% 2-Mercaptoethanol (GIBCO). All cell lines were authenticated by MSKCC Genomic Core Facility using a targeted deep sequencing assay of 585 cancer genes (HemePACT). Barcoded pools were sequenced on Illumina HiSeq 2,500 to 500-1,000× coverage per sample. Sequencing was compared with pooled normal tissue for control. We excluded mutations present in 2 databases of inherited variants (the SNP data base [dbSNP], https://www.ncbi.nlm.nih.gov/projects/SNP/, and 1000 genomes, http://www.internationalgenome.org/) and included mutations found in COSMIC. Mutations absent in the databases of inherited variant and COSMIC but found in our human lymphoma database were included. The following compounds were purchased from Selleckchem: panobinostat, SNDX-275, mocetinostat, romidepsin, SAHA, belinostat, CPI-203, ibrutinib, and S31-201. JQ1 was purchased from BPS Bioscience. Recombinant human IL-6 and IL-10 were purchased from R&D systems.
NF-κB-luciferase activity in 2 representative ABC (HBL-1 and TMD-8) cell lines. Cells were treated for 16 hours with indicated concentration of either panobinostat, ibrutinib, or the combination of the 2 drugs. Cells were incubated with 2 ng/ml of TNF-α as positive control for NF-κB activation. Error bars represent SEM of triplicates. Differences between groups were calculated with 2-way ANOVA with Bonferroni's test. **P < 0.005; ***P < 0.0005; ****P < 0.0001. (E) IL-10 level change in 3 ABC DLBCL cell lines harboring MyD88 mutation (HBL-1, TMD-8, and OCI-LY-10). Cells were treated for 12 hours with indicated concentration of either panobinostat, ibrutinib, or the combination of the 2 drugs. Error bars represent SEM of triplicates. Differences between groups were calculated with 2-way ANOVA with Bonferroni's test. **P < 0.005; ****P < 0.0001.
In vitro proliferation assay. Cells were seeded in 96-well plates at 50,000 cell/100 μl/well with either vehicle (DMSO 0.1%) or increasing concentrations of drugs for 24-72 hours. Cell viability was assessed with the nonradioactive cell proliferation MTS assay, using CellTiter 96 AQueous One Solution Reagent (Promega). The MTS reagent was added to the culture medium at 1:5 dilution, according to manufacturer's instructions. Procedures to determine the effects of certain conditions on cell proliferation and apoptosis were performed in 3 independent experiments. The 2-tailed Student t test and Wilcoxon Rank test were used to estimate the statistical significance of differences between results from the 3 experiments.
Western blotting. Cells were pelleted by centrifugation, washed once with icecold PBS, and lysed on ice for 30 minutes using the Cell Signaling lysis buffer (no. 9803) according to manufacturer's extraction protocol. Protein quantitation was done using the Direct Detect system (Millipore). A total of 30 μg of protein was denatured in Laemli buffer at 95ºC for 5 minutes, and Western immunoblotting was performed using the Bio-Rad system (TGX 4%-15% gels). Transfer was performed using the Trans Blot turbo system (Bio-Rad) into PVDF membranes. Images were acquired by using the Bio-Rad Imaging Chemidoc MP system. Secondary anti-rabbit and anti-mouse HRP-conjugated antibodies were purchased from Bio-Rad (catalogs 170-6515, 170-6516). Proteins were detected using the following antibodies purchased from Cell Signaling Technology: Acetyl-Histone H3 Lys9 PCR pathway arrays and qPCR. Total RNA was extracted with the Qiagen RNeasy mini kit protocol. A total of 1 μg of RNA was converted to cDNA using iScript cDNA synthesis kit (Bio-Rad). Real-time PCR was performed using the model CFX96 (Bio-Rad). Primers for MyD88 and GAPDH were purchased from Bio-Rad: MyD88 (qHsaCED0046947), GAPDH (qHsaCED0038674).
SiRNA experiments. siRNA transfections were performed by using the Amaxa 4D-Nucleofector Unit (Lonza). Briefly, 3 × 10 6 cells per condition were transfected with 1-2 μM siRNA or scramble, and resuspended in RPMI 10% FBS with no antibiotics. siRNAs were purchased from Invitrogen: STAT3 (catalog 4390824, clones s743 and s744), MyD88 (catalog 4390824, clone s9136), Negative Control 1 (catalog 4390643). HBL-1, TMD8, Ri-1, SUDHL-4, and OCI-LY-10 cells were transfected using the EN-150, EN-138, EN-150, DS-150, and DN-100 electroporation programs, respectively, using Solution F. Optimization was done using the Amaxa Cell Line Optimization 4D-Nucleofector X kit (catalog V4XC-9064). Transfection was performed using the 4D-Nucleofector X kit L (catalog V4XC-2024).
ELISA. Standard ELISA was performed using the human myeloid differentiation factor 88 (Myd88) ELISA kit from MyBiosource (catalog MBS086853), STAT3 pT705 kit from Abcam (catalog ab126458), human IL-6 (catalog 550799) and human IL-10 kit (catalog 550613) from BD Biosciences, according to manufacturer's instructions.
NF-κB Reporter Assays. To generate the NF-κB transcriptional reporters, HBL and TMD8 cells were first transduced with a CMV Renilla luciferase lentivirus, to be used as internal control for normalization (QIA-GEN). After hygromycin selection, cells were transduced with a NF-κB reporter lentivirus, where the expression of firefly luciferase is under control of a synthetic minimal cytomegalovirus promoter (mCMV) pro- moter and tandem repeats of the NFκB transcriptional response element (TRE) (QIAGEN). Puromycin was used for this second step of selection. For drug experiments, cells were counted and seeded in fresh media at 1 × 10 6 cells per ml before treatment for the indicated times. For shRNA experiments, cells were counted and seeded in fresh media at 1 × 10 6 cells per ml before induction for the indicated times. Luciferase activity was measured in 96-well plates by using the Dual-Luciferase Reporter Assay System (Promega) according to manufacturer's instruction. Readings were performed on a Microtiter Plate Luminometer (PerkinElmer).
MyD88 Promoter Assays. Gaussia Luciferase (GLuc) luciferase promoter was obtained from GeneCoepia with the MyD88 promoter cloned upstream of the GLuc enzyme. Normalization was done to secreted ) and Ri-1 (MyD88 WT) tumors were treated i.p. daily with either vehicle, panobinostat (5 mg/kg), ibrutinib (2mg/kg), or the 2 drugs together, 5 times weekly. Tumor volumes were measured 3 times per week. Differences between groups were calculated with the ANOVA with Dunnett's test. **P < 0.005. (B) NSG mice (n = 11 and 8 per treatment group, in TMD-8 and Ri-1 experiment, respectively) were treated i.p. daily with either vehicle, panobinostat (5 mg/kg), ibrutinib (2mg/kg), or the 2 drugs together, 5 times weekly for 3 weeks and observed until death after the end of the treatment. Differences between groups were calculated with ANOVA with Dunnett's test. ***P < 0.0005. (C) Kaplan-Meier plot of the percent survival as a function of time from last drug administration. Data are from n = 11 and 8 for all groups in TMD8 and Ri-1 tumors, respectively. ****P < 0.0001. HDAC8_55869_3596  TATAGATATAAACCGGGACCAG  HDAC8_55869_3172  TATGCTTCAATCAAAGAATGCA  HDAC8_55869_3573  ACACATACTGACATACTCGGGA  HDAC8_55869_3160  TTATGCAGTGCATATGCTTCAA  HDAC10_83933_1912  TTGAACACACAGAACCCGTTGG  HDAC10_83933_914  TGCTATACCACTGTTCACCTGC  HDAC10_83933_1396  TCTGTACTGTCATGCACACTGA  HDAC10_83933_1798  TCATCCTCAAAGAGATACTGGA  HDAC11_79885_357  TTTAGGAAATTGATCACTTTGC  HDAC11_79885_820  TAGACATCCATGATGTACACAC  HDAC11_79885_356  TTAGGAAATTGATCACTTTGCC  HDAC11_79885_360 TCTTTTAGGAAATTGATCACTT
